BiotechTube

Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to Tolterodine

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Urinary Bladder, Overactive

Conditions

Urinary Bladder, Overactive

Trial Timeline

Apr 28, 2008 → Mar 24, 2009

NCT ID
NCT00689104

About Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to Tolterodine

Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to Tolterodine is a phase 3 stage product being developed by Astellas Pharma for Urinary Bladder, Overactive. The current trial status is completed. This product is registered under clinical trial identifier NCT00689104. Target conditions include Urinary Bladder, Overactive.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT00689104Phase 3Completed
NCT00688688Phase 3Completed

Competing Products

20 competing products in Urinary Bladder, Overactive

See all competitors
ProductCompanyStageHype Score
Duloxetine + placeboEli LillyPhase 2
52
DuloxetineEli LillyPhase 2
52
Enfortumab vedotinAstellas PharmaPhase 1
33
solifenacin succinate + tamsulosin + placeboAstellas PharmaApproved
85
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
52
SolifenacinAstellas PharmaApproved
85
Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved
85
solifenacin succinateAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
SolifenacinAstellas PharmaPre-clinical
23
TamuslosinAstellas PharmaPhase 3
77
Tamsulosin + SolifenacinAstellas PharmaApproved
85
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
85
mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placeboAstellas PharmaPhase 3
77
solifenacin succinate + tolterodineAstellas PharmaPhase 3
77
TamusulosinAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
Solifenacin succinate + TolterodineAstellas PharmaPhase 3
77
Solifenacin succinate + PlaceboAstellas PharmaPhase 3
77
VesicareAstellas PharmaPre-clinical
23

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85